The Schall Law Firm Investigates XBiotech Inc. for Potential Securities Law Violations
Los Angeles, CA – The Schall Law Firm, a renowned national shareholder rights litigation firm, has announced that it is investigating potential securities laws violations by XBiotech Inc. (“XBiotech” or “the Company”) (NASDAQ: XBIT). The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose material information to investors.
Background on XBiotech Inc.
XBiotech Inc. is a clinical-stage biotechnology company based in Austin, Texas. The Company focuses on the discovery, development, and commercialization of therapeutic proteins for inflammatory conditions and immunogenic diseases. Its lead product is Xilonis, an intravenous infusion used to treat complex perianal fistulas in Crohn’s disease, which has received marketing authorization from the European Medicines Agency.
Alleged Misconduct
The Schall Law Firm’s investigation comes after a series of reports raised concerns about XBiotech’s financials and business practices. Specifically, some investors allege that the Company may have:
- Misrepresented the commercial potential of Xilonis
- Understated the risks associated with Xilonis
- Failed to disclose material information regarding clinical trials and regulatory approvals
- Engaged in insider trading
Impact on Individual Investors
If the allegations against XBiotech are proven, investors may be entitled to compensation. In securities class action lawsuits, investors can recover their losses by selling their shares before the misrepresentation was made public or by holding onto their shares and participating in a settlement. The specifics of each case depend on the particular circumstances and the evidence uncovered during the investigation.
Global Implications
The potential securities law violations by XBiotech could have significant implications for the biotechnology industry as a whole. The investigation highlights the importance of transparency and honest communication between companies and their investors. It also underscores the need for robust regulatory oversight to protect investors from fraudulent activities and ensure that companies adhere to the highest ethical standards.
Conclusion
The Schall Law Firm’s investigation into XBiotech Inc. is an important reminder for investors to be diligent and vigilant when considering potential investments in the biotechnology sector. As the industry continues to evolve, it is crucial that companies maintain transparency and honesty in their dealings with the public. The outcome of this investigation could set a precedent for future cases and shape the way the industry approaches disclosures and investor relations.
If you are an investor in XBiotech and believe you have suffered a loss, you may be entitled to compensation. Contact The Schall Law Firm for a free consultation.
For more information, please contact:
The Schall Law Firm
Brian Schall, Esq.
1880 Century Park East, Suite 406
Los Angeles, CA 90067
310-301-3335
The Schall Law Firm represents investors worldwide and works on contingency, meaning there is no cost to clients.
The Schall Law Firm has significant experience in prosecuting securities class action lawsuits and has recovered billions of dollars for investors.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of professional conduct.
